Compare Biocon Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ASTRAZENECA PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ASTRAZENECA PHARMA BIOCON /
ASTRAZENECA PHARMA
 
P/E (TTM) x 17.0 74.1 23.0% View Chart
P/BV x 2.6 20.9 12.6% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 BIOCON    ASTRAZENECA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
ASTRAZENECA PHARMA
Mar-18
BIOCON /
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1881,278 93.0%   
Low Rs305883 34.6%   
Sales per share (Unadj.) Rs68.7228.4 30.1%  
Earnings per share (Unadj.) Rs7.610.4 72.9%  
Cash flow per share (Unadj.) Rs14.016.3 85.9%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.398.8 87.4%  
Shares outstanding (eoy) m600.0025.00 2,400.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.7 229.7%   
Avg P/E ratio x98.9104.2 94.8%  
P/CF ratio (eoy) x53.466.4 80.4%  
Price / Book Value ratio x8.610.9 79.0%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,90027,008 1,658.4%   
No. of employees `0006.11.4 453.5%   
Total wages/salary Rs m9,3111,535 606.5%   
Avg. sales/employee Rs Th6,705.84,210.9 159.2%   
Avg. wages/employee Rs Th1,514.21,132.2 133.7%   
Avg. net profit/employee Rs Th736.9191.1 385.6%   
INCOME DATA
Net Sales Rs m41,2345,710 722.1%  
Other income Rs m2,062123 1,683.3%   
Total revenues Rs m43,2965,833 742.3%   
Gross profit Rs m8,291463 1,791.1%  
Depreciation Rs m3,851147 2,612.6%   
Interest Rs m6150-   
Profit before tax Rs m5,887438 1,344.1%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569179 877.0%   
Profit after tax Rs m4,531259 1,748.7%  
Gross profit margin %20.18.1 248.0%  
Effective tax rate %26.740.8 65.3%   
Net profit margin %11.04.5 242.2%  
BALANCE SHEET DATA
Current assets Rs m41,4863,209 1,292.7%   
Current liabilities Rs m21,4132,070 1,034.7%   
Net working cap to sales %48.720.0 243.9%  
Current ratio x1.91.6 124.9%  
Inventory Days Days6472 88.4%  
Debtors Days Days9435 269.7%  
Net fixed assets Rs m50,661790 6,410.4%   
Share capital Rs m3,00050 6,000.0%   
"Free" reserves Rs m48,8082,419 2,017.4%   
Net worth Rs m51,8082,469 2,098.1%   
Long term debt Rs m17,8980-   
Total assets Rs m99,8974,605 2,169.1%  
Interest coverage x10.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.41.2 33.3%   
Return on assets %5.25.6 91.6%  
Return on equity %8.710.5 83.3%  
Return on capital %9.617.7 54.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,058300 4,025.4%   
Fx outflow Rs m7,3482,015 364.7%   
Net fx Rs m4,710-1,715 -274.6%   
CASH FLOW
From Operations Rs m6,62188 7,532.4%  
From Investments Rs m-6,840-94 7,307.7%  
From Financial Activity Rs m-2,397NA-  
Net Cashflow Rs m-2,612-6 45,824.6%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 15.7 68.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 12,856 855.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Petrol and Diesel Prices, DHFL Saga, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their trading session marginally higher yesterday. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 18, 2019 (Close)

TRACK BIOCON

BIOCON - SANOFI INDIA COMPARISON

COMPARE BIOCON WITH

MARKET STATS